Pharmacy Disclosure Log 2024

1. Acute Myeloid Leukaemia Response 256
2. Atopic Dermatitis Response 472
3. Allogeneic Stem Cell Transplants Response 268
4. Allogeneic Stem Cell Transplants Response 268 - Attachment
5. Alpha-1 Proteinase-Inhibitor Response 095
6. Ammonia Blood Testing Response 406
7. Asthma Response 235
8. Asthma Treatment Response 486
9. Biliary Tract and Non-Small Cell Lung Cancer Treatment Response 244
10. Biologic and Targeted Medications Response 215
11. Biologic Medicines in Gastroenterology Response 362
12. Biologic Medicines in Dermatology Response 022
13. Biologic Medicines in Gastroenterology Response 076
14. Biologic and Biosimilar Response 295
15. Biologic Medicines in Dermatology Response 293
16. Blood Monitoring Devices Response 294
17. Blood Test Volumes Response 270
18. Breast Cancer Response 110
19. Cancer Treatment using Specified Products Response 379
20. Colorectal Cancer Response 169
21. Colorectal Cancer Response 430
22. Diffuse Large B Cell Lymphoma Response 425
23. Endometrial Cancer Response 427
24. GCA and HS Response 038
25. GCA and HS Response 038-Attachment1
26. Giant Cell Arteritis Response 301
27. Giant Cell Arteritis Response 8427 -Attachment
28. Haematology and Immunoglobulin Treatments Response175
29. Haematology and Immunoglobulin Treatments Response 414
30. Hidradenitis Suppurativa Response 429
31. Hidradenitis Suppurativa Response 429 - Attachment
32. Immunology Response 144
33. Intra-Vitreal Injections or Implants Response 028
34. Intra-Vitreal Injections or Implant Response 305
35. Intravitreal Treatments for any Eye Condition Response 089
36. Intra-Vitreal Treatments Response 391
37. Lung Cancer Response 120
38. Medications within Dermatology Response 469
39. Metastatic Renal Cell Carcinoma Response 225
40. Migraine Response 188
41. Migraine Response 371
42. Multiple Myeloma Response 273
43. Myelofibrosis Response 165
44. Myelofibrosis Response 165 -Attachment 1
45. Myelofibrosis Response 418
46. Myelofibrosis Response 418 - Attachment
47. Newly Diagnosed Patients with AML Response 503
48. Non-Small Cell Lung Cancer Response 374
49. Oncology Breast Cancer Response 358
50. Oncology Supplemental Response 180
51. Oncology Supplemental Response 438
52. Oncology Treatment by Therapies Response 292
53. Patients Treated for any Disease Response 337
54. Patients Treated for any Disease Response 337 - Attachment
55. Patients Treated with Specific Medicines Response 477
56. Patients Treated with Specific Medicines Response 477 - Attachment
57. Pharmaceutical Companies Response 381
58. Posology of Enoxaparin Response 434
59. Prescription CBPMs Response 112
60. Renal Cell Carcinoma Response 192
61. Renal Cell Carcinoma Response 192 - Attachment
62. Renal Cell Carcinoma Response 383
63. Renal Cell Carcinoma Request 383 - Attachment
64. Starvation Ketoacidosis Response 445
65. Starvation Ketoacidosis Response 445 - Attachment
66. Rheumatology Department Response 008
67. Treatment with Specified Products Response 047
68. Treatment of Cancers Response 212
69. Treatment of Dermatological Conditions Response 219
70. Urothelial and Endometrial Cancer Response 247
71. Waldenström Macroglobulinemia Patients Response 455

 

 

• Share:
• Facebook
• Twitter
• LinkedIn